The experimental antibody-drug conjugate trastuzumab emtansine (T-DM1) has shown significant improvement in progression-free survival (PFS) compared with capecitabine plus lapatinib among patients with HER2+ locally advanced or metastatic breast cancer (MBC).

Adjuvant therapy including 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC) followed by weekly paclitaxel was associated with a slight but significant improvement in disease-free survival.

Several analyses of the international randomized phase 3 Breast Cancer Trials of Oral Everolimus-2 (BOLERO-2) plus exemestane versus exemestane alone for the treatment of postmenopausal women.

Taxane-based chemotherapy combined with lapatinib results in shorter progression-free survival (PFS) than with trastuzumab as first-line treatment for patients with HER2+ metastatic breast cancer.

The potent, oral, pan-BCR-ABL inhibitor ponatinib has demonstrated robust antileukemic activity in a heavily pretreated population of patients with chronic myelogenous leukemia or Ph positive (Ph+) acute lymphoblastic leukemia who are resistant or intolerant to dasatinib or nilotinib or have the T315I mutation.

The first-in-class, oral, potent, and selective small-molecule competitive inhibitor of anaplastic lymphoma kinase (ALK), crizotinib, was found to have a durable overall response rate and a median progression-free survival of 8.1 months in patients with ALK-positive non–small-cell lung cancer (NSCLC).

Pomalidomide in combination with low-dose dexamethasone has shown a 30% overall response rate in patients with multiple myeloma refractory to lenalidomide, bortezomib, or both, including those with prior transplant.

The combination of carfilzomib, lenalidomide, and low-dose dexamethasone has been shown to be highly active in patients with newly diagnosed multiple myeloma and provides rapid and deep responses.

Patients with metastatic cancer who received early palliative care intervention had immediate improvement in satisfaction with care and later improvement in quality of life (QOL) and symptom control compared with standard care.

Continuous androgen deprivation may be a preferred treatment option for hormone-sensitive metastatic prostate cancer in men with minimal disease spread, according to results of a long-term international phase 3 trial reported at the 2012 Annual Meeting of the American Society of Clinical Oncology.

Patients with asymptomatic and mildly symptomatic chemotherapy-naïve metastatic castration-resistant prostate cancer had significantly improved radiographic progression-free survival (rPFS) and showed a strong trend for increased overall survival (OS) following treatment with abiraterone acetate plus prednisone compared with prednisone alone.